Literature DB >> 33603749

Advances in Human Immune System Mouse Models for Studying Human Hematopoiesis and Cancer Immunotherapy.

Syed A Mian1,2, Fernando Anjos-Afonso3, Dominique Bonnet1.   

Abstract

Immunotherapy has established itself as a promising tool for cancer treatment. There are many challenges that remain including lack of targets and some patients across various cancers who have not shown robust clinical response. One of the major problems that have hindered the progress in the field is the dearth of appropriate mouse models that can reliably recapitulate the complexity of human immune-microenvironment as well as the malignancy itself. Immunodeficient mice reconstituted with human immune cells offer a unique opportunity to comprehensively evaluate immunotherapeutic strategies. These immunosuppressed and genetically modified mice, with some overexpressing human growth factors, have improved human hematopoietic engraftment as well as created more functional immune cell development in primary and secondary lymphoid tissues in these mice. In addition, several new approaches to modify or to add human niche elements to further humanize these immunodeficient mice have allowed a more precise characterization of human hematopoiesis. These important refinements have opened the possibility to evaluate not only human immune responses to different tumor cells but also to investigate how malignant cells interact with their niche and most importantly to test immunotherapies in a more preclinically relevant setting, which can ultimately lead to better success of these drugs in clinical trials.
Copyright © 2021 Mian, Anjos-Afonso and Bonnet.

Entities:  

Keywords:  human hematopoiesis; immune reconstitution; immunodeficient mice models; immunotherapy; xenotransplantation models

Year:  2021        PMID: 33603749      PMCID: PMC7884350          DOI: 10.3389/fimmu.2020.619236

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  134 in total

1.  Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells.

Authors:  A J BECKER; E A McCULLOCH; J E TILL
Journal:  Nature       Date:  1963-02-02       Impact factor: 49.962

2.  Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice.

Authors:  Kaori Sango; Aviva Joseph; Mahesh Patel; Kristin Osiecki; Monica Dutta; Harris Goldstein
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

3.  Implantable microenvironments to attract hematopoietic stem/cancer cells.

Authors:  Jungwoo Lee; Matthew Li; Jack Milwid; Joshua Dunham; Claudio Vinegoni; Rostic Gorbatov; Yoshiko Iwamoto; Fangjing Wang; Keyue Shen; Kimberley Hatfield; Marianne Enger; Sahba Shafiee; Emmet McCormack; Benjamin L Ebert; Ralph Weissleder; Martin L Yarmush; Biju Parekkadan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

4.  AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.

Authors:  M Wunderlich; F-S Chou; K A Link; B Mizukawa; R L Perry; M Carroll; J C Mulloy
Journal:  Leukemia       Date:  2010-08-05       Impact factor: 11.528

5.  Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells.

Authors:  Katsuto Takenaka; Tatiana K Prasolava; Jean C Y Wang; Steven M Mortin-Toth; Sam Khalouei; Olga I Gan; John E Dick; Jayne S Danska
Journal:  Nat Immunol       Date:  2007-11-04       Impact factor: 25.606

6.  NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration.

Authors:  F E Nicolini; J D Cashman; D E Hogge; R K Humphries; C J Eaves
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

7.  Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.

Authors:  Niwa Ali; Barry Flutter; Robert Sanchez Rodriguez; Ehsan Sharif-Paghaleh; Linda D Barber; Giovanna Lombardi; Frank O Nestle
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

8.  Improved multilineage human hematopoietic reconstitution and function in NSGS mice.

Authors:  Mark Wunderlich; Fu-Sheng Chou; Christina Sexton; Pietro Presicce; Claire A Chougnet; Julio Aliberti; James C Mulloy
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

9.  Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model.

Authors:  Rintaro Ono; Takashi Watanabe; Eiryo Kawakami; Makoto Iwasaki; Mariko Tomizawa-Murasawa; Masashi Matsuda; Yuho Najima; Shinsuke Takagi; Saera Fujiki; Rumi Sato; Yoshiki Mochizuki; Hisahiro Yoshida; Kaoru Sato; Hiromasa Yabe; Shunichi Kato; Yoriko Saito; Shuichi Taniguchi; Leonard D Shultz; Osamu Ohara; Masayuki Amagai; Haruhiko Koseki; Fumihiko Ishikawa
Journal:  EBioMedicine       Date:  2019-02-13       Impact factor: 8.143

10.  Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.

Authors:  Lukasz Kuryk; Anne-Sophie W Møller; Magnus Jaderberg
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

View more
  1 in total

1.  An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity.

Authors:  Xuedan He; Shiqi Zhou; Breandan Quinn; Dushyant Jahagirdar; Joaquin Ortega; Mark D Long; Scott I Abrams; Jonathan F Lovell
Journal:  Cancer Immunol Res       Date:  2022-03-01       Impact factor: 12.020

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.